Charles Schwab Investment Management Inc. Acquires 89,940 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Charles Schwab Investment Management Inc. grew its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 13.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 744,050 shares of the biotechnology company’s stock after purchasing an additional 89,940 shares during the period. Charles Schwab Investment Management Inc. owned about 0.52% of Aurinia Pharmaceuticals worth $5,454,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Aurinia Pharmaceuticals by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 1,531,617 shares of the biotechnology company’s stock worth $7,673,000 after acquiring an additional 21,119 shares in the last quarter. Segall Bryant & Hamill LLC grew its stake in shares of Aurinia Pharmaceuticals by 1.6% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 562,775 shares of the biotechnology company’s stock worth $4,125,000 after purchasing an additional 9,031 shares during the period. SG Americas Securities LLC boosted its stake in shares of Aurinia Pharmaceuticals by 4,307.9% during the 3rd quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company’s stock worth $4,015,000 after acquiring an additional 535,301 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Aurinia Pharmaceuticals by 18.8% in the second quarter. Bank of New York Mellon Corp now owns 488,721 shares of the biotechnology company’s stock valued at $2,791,000 after purchasing an additional 77,510 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Aurinia Pharmaceuticals in the 3rd quarter valued at $3,330,000. Institutional investors own 36.83% of the company’s stock.

Insider Transactions at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Jeffrey Allen Bailey sold 4,557 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $8.43, for a total transaction of $38,415.51. Following the transaction, the director now directly owns 13,356 shares of the company’s stock, valued at $112,591.08. The trade was a 25.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

AUPH has been the topic of a number of research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 price target on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. StockNews.com upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, November 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Aurinia Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $10.00.

Aurinia Pharmaceuticals Price Performance

Shares of AUPH opened at $9.69 on Friday. Aurinia Pharmaceuticals Inc. has a fifty-two week low of $4.71 and a fifty-two week high of $10.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The firm has a 50-day simple moving average of $7.99 and a 200-day simple moving average of $6.71. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of -64.60 and a beta of 1.41.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.